Mitsubishi UFJ Trust & Banking Corp Has $21.37 Million Position in BioNTech SE (NASDAQ:BNTX)

Mitsubishi UFJ Trust & Banking Corp trimmed its stake in BioNTech SE (NASDAQ:BNTX) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 187,516 shares of the company’s stock after selling 3,026 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in BioNTech were worth $21,367,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Jones Financial Companies Lllp boosted its position in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. boosted its holdings in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares in the last quarter. GAMMA Investing LLC grew its stake in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares during the period. Generali Investments CEE investicni spolecnost a.s. bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $137,000. Finally, AlphaCentric Advisors LLC acquired a new position in shares of BioNTech during the fourth quarter worth approximately $168,000. 15.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on BNTX. BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company. Morgan Stanley dropped their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. Citigroup assumed coverage on BioNTech in a report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. Finally, Wells Fargo & Company started coverage on BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price on the stock. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Stock Performance

Shares of BNTX stock opened at $95.40 on Friday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The firm’s 50-day simple moving average is $111.75 and its two-hundred day simple moving average is $113.59. The firm has a market cap of $22.89 billion, a price-to-earnings ratio of -45.43 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the business earned $1.90 earnings per share. BioNTech’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, equities analysts forecast that BioNTech SE will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.